<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904588</url>
  </required_header>
  <id_info>
    <org_study_id>ACCESS</org_study_id>
    <nct_id>NCT04904588</nct_id>
  </id_info>
  <brief_title>HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for International Blood and Marrow Transplant Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for International Blood and Marrow Transplant Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation&#xD;
      (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral&#xD;
      blood stem cell transplant in adults and bone marrow stem cell transplant in children.&#xD;
      Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be&#xD;
      used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well&#xD;
      this treatment works in patients with hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year post HCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>1 year post-HCT</time_frame>
    <description>Defined as graft failure, relapse or progression of underlying disease, death, grade 3-4 acute GVHD, or NIH-severe chronic GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD, relapse free survival</measure>
    <time_frame>1 year post-HCT</time_frame>
    <description>Defined as relapse or progression of underling disease, graft failure, grade III-IV acute GVHD, chronic GVHD requiring systemic immune suppression, or death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified GVHD, relapse free survival</measure>
    <time_frame>1 year post-HCT</time_frame>
    <description>Defined as relapse or progression of underling disease, graft failure, grade III-IV acute GVHD, NIH moderate or severe chronic GVHD, or death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of nonrelapse mortality</measure>
    <time_frame>Day +100 and 1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival based on donor HLA match grade and donor age (7/8 versus &lt;7/8)</measure>
    <time_frame>1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival based on donor HLA match grade and donor age (7/8 versus &lt;7/8)</measure>
    <time_frame>1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of neutrophil recovery</measure>
    <time_frame>Day +100 post-HCT</time_frame>
    <description>Defined as neutrophil count ≥500/mm^3 for 3 consecutive days post-HCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of neutrophil recovery</measure>
    <time_frame>Day +100 post-HCT</time_frame>
    <description>Defined as the evaluation of the time it takes for neutrophil count recovery to occur in the study subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of platelet recovery</measure>
    <time_frame>Day +100 post-HCT</time_frame>
    <description>Defined as platelet count ≥20,000/mm^3 or ≥50,000/mm^3 with no platelet transfusions within seven days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of platelet recovery</measure>
    <time_frame>Day +100 post-HCT</time_frame>
    <description>Defined as the evaluation of the time it takes for platelet count recovery to occur in the study subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of primary graft failure</measure>
    <time_frame>Day +28 post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor chimerism</measure>
    <time_frame>Day +100 post-HCT</time_frame>
    <description>Strata 2 and 3 only. Percent of donor chimerism via peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute GVHD</measure>
    <time_frame>Day +100 post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic GVHD</measure>
    <time_frame>1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of BK and cytomegalovirus (CMV) viral infections</measure>
    <time_frame>Days +100 and +180 post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse/progression</measure>
    <time_frame>1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cytokine release syndrome (CRS)</measure>
    <time_frame>Day +14 post-HCT</time_frame>
    <description>Overall incidence of CRS of any grade and grade 3 or 4 CRS post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of secondary graft failure</measure>
    <time_frame>1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Toxicity</measure>
    <time_frame>1 year post-HCT</time_frame>
    <description>To tabulate adverse events (AEs) experienced by recipients, defined as grade 3-5 unexpected and Grade 5 expected AEs, according to CTCAE version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <condition>Acute Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Regimen A (MAC: busulfan and fludarabine, PBSC HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive:&#xD;
Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3&#xD;
Fludarabine (150 mg/m2 total dose) IV on days -6 to -2&#xD;
Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B (MAC: Fludarabine and TBI; PBSC HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive:&#xD;
Fludarabine (90 mg/m2 total dose) IV on days -7 to -5&#xD;
Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1&#xD;
Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive:&#xD;
Fludarabine (120-180 mg/m2 total dose) IV on days -6 to -2&#xD;
Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4&#xD;
Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive:&#xD;
Fludarabine (120-180 mg/m2 total dose) IV on days -7 to -3&#xD;
Melphalan (100-140 mg/m2) IV on day -1&#xD;
Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive:&#xD;
Fludarabine (150 mg/m2 total dose) IV on days -6 to -2&#xD;
Cyclophosphamide (29-50 mg/kg) IV on days -6 and -5&#xD;
TBI (200 cGy) on day -1&#xD;
Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive:&#xD;
Busulfan (dosed by age and weight per institutional standards to target goal pharmacokinetic (PK) in range noted in protocol.) on days -6 to -3&#xD;
Cyclophosphamide (100 mg/kg total dose) IV on days -2 and -1&#xD;
Patients receive a bone marrow (BM) graft infusion from a mismatched unrelated donor on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive:&#xD;
Cyclophosphamide (100 mg/kg total dose) IV on days -5 and -4&#xD;
TBI (1200 cGy total dose) on days -3, -2 and -1&#xD;
Patients receive a BM graft infusion from a mismatched unrelated donor on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV or PO pre-transplant as part of conditioning regimen</description>
    <arm_group_label>Regimen A (MAC: busulfan and fludarabine, PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)</arm_group_label>
    <other_name>Busulfex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV pre-transplant as part of conditioning regimen</description>
    <arm_group_label>Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)</arm_group_label>
    <other_name>Busulfex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV pre-transplant as part of conditioning regimen</description>
    <arm_group_label>Regimen A (MAC: busulfan and fludarabine, PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen B (MAC: Fludarabine and TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)</arm_group_label>
    <other_name>Fludara®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-body irradiation</intervention_name>
    <description>Administered pre-transplant as part of conditioning regimen</description>
    <arm_group_label>Regimen B (MAC: Fludarabine and TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV pre-transplant as part of conditioning regimen</description>
    <arm_group_label>Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)</arm_group_label>
    <arm_group_label>Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV pre-transplant as part of conditioning regimen</description>
    <arm_group_label>Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PBSC Hematopoietic Stem Cell Transplantation (HSCT)</intervention_name>
    <description>Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.</description>
    <arm_group_label>Regimen A (MAC: busulfan and fludarabine, PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen B (MAC: Fludarabine and TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)</arm_group_label>
    <other_name>PBSC HSCT</other_name>
    <other_name>PBSC HCT</other_name>
    <other_name>PBSC Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Bone marrow graft is infused from a mismatched unrelated donor on Day 0.</description>
    <arm_group_label>Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)</arm_group_label>
    <arm_group_label>Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)</arm_group_label>
    <other_name>BM HSCT</other_name>
    <other_name>BM HCT</other_name>
    <other_name>Bone Marrow Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-transplant Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.</description>
    <arm_group_label>Regimen A (MAC: busulfan and fludarabine, PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen B (MAC: Fludarabine and TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)</arm_group_label>
    <arm_group_label>Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.</description>
    <arm_group_label>Regimen A (MAC: busulfan and fludarabine, PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen B (MAC: Fludarabine and TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)</arm_group_label>
    <arm_group_label>Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)</arm_group_label>
    <other_name>Mesnex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.</description>
    <arm_group_label>Regimen A (MAC: busulfan and fludarabine, PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen B (MAC: Fludarabine and TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)</arm_group_label>
    <arm_group_label>Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.</description>
    <arm_group_label>Regimen A (MAC: busulfan and fludarabine, PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen B (MAC: Fludarabine and TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)</arm_group_label>
    <arm_group_label>Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>Cellcept®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient-Reported Outcomes</intervention_name>
    <description>Survey assessments will be administered to study participants pre- and post-transplant.</description>
    <arm_group_label>Regimen A (MAC: busulfan and fludarabine, PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen B (MAC: Fludarabine and TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)</arm_group_label>
    <arm_group_label>Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)</arm_group_label>
    <arm_group_label>Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Stratum 1 Recipient Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years and &lt; 66 years (chemotherapy-based conditioning) or &lt; 61 years (total&#xD;
             body irradiation [TBI]-based conditioning) at the time of signing informed consent&#xD;
&#xD;
          2. Planned MAC regimen as defined per protocol&#xD;
&#xD;
          3. Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with&#xD;
             age &lt; 35 years&#xD;
&#xD;
          4. Product planned for infusion is PBSC&#xD;
&#xD;
          5. HCT Comorbidity Index (HCT-CI) &lt; 5&#xD;
&#xD;
          6. One of the following diagnoses:&#xD;
&#xD;
               1. Acute myelogenous leukemia (AML) in 1st remission or beyond with ≤ 5% marrow&#xD;
                  blasts and no circulating blasts or evidence of extra-medullary disease.&#xD;
                  Documentation of bone marrow assessment will be accepted within 45 days prior to&#xD;
                  the anticipated start of conditioning.&#xD;
&#xD;
               2. Acute lymphoblastic leukemia (ALL) in 1st remission or beyond with ≤ 5% marrow&#xD;
                  blasts and no circulating blasts or evidence of extra-medullary disease.&#xD;
                  Documentation of bone marrow assessment will be accepted within 45 days prior to&#xD;
                  the anticipated start of conditioning.&#xD;
&#xD;
               3. Patients with myelodysplastic syndrome (MDS) with no circulating blasts and with&#xD;
                  &lt; 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to&#xD;
                  lack of differences in outcomes with &lt; 5% or 5-10% blasts in MDS). Documentation&#xD;
                  of bone marrow assessment will be accepted within 45 days prior to the&#xD;
                  anticipated start of conditioning.&#xD;
&#xD;
          7. Cardiac function: Left ventricular ejection fraction &gt; 45% based on most recent&#xD;
             echocardiogram or multigated acquisition scan (MUGA) results&#xD;
&#xD;
          8. Estimated creatinine clearance &gt; 60 mL/min calculated by equation&#xD;
&#xD;
          9. Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO)&#xD;
             corrected for hemoglobin &gt; 50% and forced expiratory volume in first second (FEV1)&#xD;
             predicted &gt; 50% based on most recent DLCO results&#xD;
&#xD;
         10. Liver function acceptable per local institutional guidelines&#xD;
&#xD;
         11. Karnofsky performance status (KPS) of &gt; 70%&#xD;
&#xD;
         12. Subjects ≥ 18 years of age must have the ability to give informed consent according to&#xD;
             applicable regulatory and local institutional requirements.&#xD;
&#xD;
        Stratum 2 Recipient Inclusion Criteria&#xD;
&#xD;
          1. Age &gt; 18 years at the time of signing informed consent&#xD;
&#xD;
          2. Planned NMA/RIC regimen as defined per protocol&#xD;
&#xD;
          3. Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with&#xD;
             age &lt; 35 years&#xD;
&#xD;
          4. Product planned for infusion is PBSC&#xD;
&#xD;
          5. One of the following diagnoses:&#xD;
&#xD;
               1. Patients with acute leukemia or chronic myelogenous leukemia (CML) with no&#xD;
                  circulating blasts, no evidence of extramedullary disease, and with &lt; 5% blasts&#xD;
                  in the bone marrow. Documentation of bone marrow assessment will be accepted&#xD;
                  within 45 days prior to the anticipated start of conditioning.&#xD;
&#xD;
               2. Patients with MDS with no circulating blasts and with &lt; 10% blasts in the bone&#xD;
                  marrow (higher blast percentage allowed in MDS due to lack of differences in&#xD;
                  outcomes with &lt; 5% or 5-10% blasts in MDS.) Documentation of bone marrow&#xD;
                  assessment will be accepted within 45 days prior to the anticipated start of&#xD;
                  conditioning.&#xD;
&#xD;
               3. Patients with relapsed chronic lymphocytic leukemia (CLL) with chemosensitive&#xD;
                  disease at time of transplantation&#xD;
&#xD;
               4. Patients with lymphoma with chemosensitive disease at the time of transplantation&#xD;
&#xD;
          6. Cardiac function: Left ventricular ejection fraction &gt; 45% based on most recent&#xD;
             echocardiogram or MUGA results with no clinical evidence of heart failure&#xD;
&#xD;
          7. Estimated creatinine clearance &gt; 60 mL/min calculated by equation&#xD;
&#xD;
          8. Pulmonary function: DLCO corrected for hemoglobin &gt; 50% and FEV1 predicted &gt; 50% based&#xD;
             on most recent DLCO results&#xD;
&#xD;
          9. Liver function acceptable per local institutional guidelines&#xD;
&#xD;
         10. KPS of &gt; 60%&#xD;
&#xD;
         11. Subjects ≥ 18 years of age must have the ability to give informed consent according to&#xD;
             applicable regulatory and local institutional requirements.&#xD;
&#xD;
        Stratum 3 Recipient Inclusion Criteria&#xD;
&#xD;
          1. Age &gt; 1 years and &lt; 21 years at the time of signing informed consent&#xD;
&#xD;
          2. Partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age &lt; 35&#xD;
             years&#xD;
&#xD;
          3. Product planned for infusion is BM&#xD;
&#xD;
          4. Planned MAC regimen as defined per protocol&#xD;
&#xD;
          5. One of the following diagnosis:&#xD;
&#xD;
               1. AML in 1st remission or beyond with ≤ 5% marrow blasts, no circulating blasts or&#xD;
                  evidence of extra-medullary disease. Pre-transplant MRD testing will be performed&#xD;
                  as per standard of practice at the treating institution. Patients with any MRD&#xD;
                  status are eligible and should be enrolled at the discretion of provider.&#xD;
                  Documentation of bone marrow assessment will be accepted within 45 days prior to&#xD;
                  the anticipated start of conditioning.&#xD;
&#xD;
               2. Patients MDS with no circulating blasts and less than 10% blasts in the bone&#xD;
                  marrow. Documentation of bone marrow assessment will be accepted within 45 days&#xD;
                  prior to the anticipated start of conditioning.&#xD;
&#xD;
               3. ALL in 1st remission or beyond with ≤ 5% marrow blasts, no circulating blasts, or&#xD;
                  evidence of extra-medullary disease. Pre-transplant MRD testing will be performed&#xD;
                  as standard practice at the treating institution with the goal of achieving MRD&#xD;
                  of &lt;0.01%. Patients with any MRD status are eligible and should be enrolled at&#xD;
                  the discretion of provider. Documentation of bone marrow assessment will be&#xD;
                  accepted within 45 days prior to the anticipated start of conditioning.&#xD;
&#xD;
               4. Other leukemia (mixed-phenotype acute leukemia [MPAL], CML) in morphologic&#xD;
                  remission with ≤ 5% marrow blasts and no circulating blasts or evidence of&#xD;
                  extramedullary disease. Documentation of bone marrow assessment will be accepted&#xD;
                  within 45 days prior to the anticipated start of conditioning.&#xD;
&#xD;
               5. Chemotherapy sensitive lymphoma in at least partial remission (PR)&#xD;
&#xD;
          6. KPS or Lansky performance score ≥ 70%&#xD;
&#xD;
          7. Cardiac function: Left ventricular ejection fraction of ≥ 50% and shortening fraction&#xD;
             of ≥ 27% based on most recent echocardiogram&#xD;
&#xD;
          8. Glomerular Filtration Rate (GFR) of ≥ 60ml/min/1.73m2 measured by nuclear medicine&#xD;
             scan or calculated from a 24 hour urine collection&#xD;
&#xD;
          9. Pulmonary function: DLCO corrected for hemoglobin, FEV1, Forced Vital Capacity (FVC)&#xD;
             of ≥50% if able to perform pulmonary function tests. If unable to perform pulmonary&#xD;
             function tests, must have a resting pulse oximetry of &gt;92% without supplemental&#xD;
             oxygen.&#xD;
&#xD;
         10. Hepatic: Total bilirubin ≤ 2.5 mg/dL and alanine aminotransferase (ALT), aspartate&#xD;
             aminotransferase (AST) &lt; 3x the upper limit of normal&#xD;
&#xD;
         11. Legal guardian permission must be obtained for subjects &lt; 18 years of age. Pediatric&#xD;
             subjects will be included in age appropriate discussion in order to obtain assent.&#xD;
&#xD;
         12. Subjects ≥ 18 years of age must have the ability to give informed consent according to&#xD;
             applicable regulatory and local institutional requirements.&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          1. Must be unrelated to the subject and high-resolution HLA-matched at 4/8, 5/8, 6/8, or&#xD;
             7/8 (HLA-A, -B, -C, and -DRB1)&#xD;
&#xD;
          2. Donor must be typed at high-resolution for a minimum of HLA-A, -B, -C, -DRB1, -DQB1,&#xD;
             and -DPB1&#xD;
&#xD;
          3. Age &gt; 18 years and &lt; 35 years at the time of signing informed consent&#xD;
&#xD;
          4. Meet the donor registries' medical suitability requirements for PBSC or BM donation&#xD;
&#xD;
          5. Must undergo eligibility screening according to current Food and Drug Administration&#xD;
             (FDA) requirements. Donors who do not meet one or more of the donor screening&#xD;
             requirements may donate under urgent medical need.&#xD;
&#xD;
          6. Must agree to donate PBSC (or BM for stratum 3)&#xD;
&#xD;
          7. Must have the ability to give standard (non-study) informed consent according to&#xD;
             applicable donor regulatory requirements&#xD;
&#xD;
        Recipient Exclusion Criteria (Strata 1, 2 and 3):&#xD;
&#xD;
          1. Suitable HLA-matched related or 8/8 high-resolution matched unrelated donor available&#xD;
&#xD;
          2. Subject unwilling or unable to give informed consent, or unable to comply with the&#xD;
             protocol including required follow-up and testing&#xD;
&#xD;
          3. Primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia,&#xD;
             polycythemia vera, or MDS with grade 4 marrow fibrosis&#xD;
&#xD;
          4. Subjects with a prior allogeneic transplant or autologous transplant within the past 3&#xD;
             months&#xD;
&#xD;
          5. Females who are breast-feeding or pregnant&#xD;
&#xD;
          6. Uncontrolled bacterial, viral or fungal infection at the time of the transplant&#xD;
             preparative regimen&#xD;
&#xD;
          7. Concurrent enrollment on other interventional GVHD clinical trial (enrollment on&#xD;
             supportive care trials may be allowed after discussion with Principal Investigators)&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          1. Donor unwilling or unable to donate&#xD;
&#xD;
          2. Recipient positive anti-donor HLA antibodies against a mismatched HLA in the selected&#xD;
             donor determined by either:&#xD;
&#xD;
               1. a positive crossmatch test of any titer (by complement-dependent cytotoxicity or&#xD;
                  flow cytometric testing) or&#xD;
&#xD;
               2. the presence of anti-donor HLA antibody to any HLA locus (HLA-A, -B, -C, -DRB1,&#xD;
                  -DQB1, -DQA1, -DPB1, -DPA1) with mean fluorescence intensity (MFI) &gt;3000 by solid&#xD;
                  phase immunoassay&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Devine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NMDP/Be The Match</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janelle Olson, PhD</last_name>
    <phone>763-406-8147</phone>
    <email>jolson@nmdp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Leckrone</last_name>
    <phone>763-406-5124</phone>
    <email>eleckron@nmdp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monzr Al Malki, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Shaffer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ballen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John McCarty, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Preleukemia</keyword>
  <keyword>Precursor Cell Lymphoblastic Leukemia-Lymphoma</keyword>
  <keyword>Leukemia, Lymphocytic, Chronic, B-Cell</keyword>
  <keyword>Leukemia, Myeloid, Acute</keyword>
  <keyword>Leukemia, Biphenotypic, Acute</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Bone Marrow Diseases</keyword>
  <keyword>Precancerous Conditions</keyword>
  <keyword>Leukemia, Lymphoid</keyword>
  <keyword>Leukemia, B-Cell</keyword>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Mesna</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Total Body Irradiation</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Unrelated Donors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

